Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | GPR6 | P46095 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | USP14 | P54578 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31269049 | 0.92 | GPR119 (0.37) | GPR119HCRTR1HCRTR2CNR1CNR2 | |
| SCHEMBL31269194 | 0.88 | TLR7 (0.36) | GPR119HCRTR1HCRTR2CNR2PIK3CD | |
| SCHEMBL31268830 | 0.88 | DPP4 (0.35) | GPR119CNR1PIK3CDDGAT1 | |
| SCHEMBL31268995 | 0.88 | DPP4 (0.40) | GPR119PIK3CD | |
| SCHEMBL31269337 | 0.87 | CNR1 (0.39) | GPR119CNR1CNR2PIK3CDDGAT1 | |
| SCHEMBL31268788 | 0.86 | PIK3CD (0.37) | CNR1CNR2PIK3CDDGAT1 | |
| SCHEMBL31269294 | 0.86 | TLR7 (0.35) | GPR119PIK3CDDGAT1 | |
| SCHEMBL31269283 | 0.85 | PIK3CD (0.38) | CNR1CNR2PIK3CDDGAT1 | |
| SCHEMBL31268747 | 0.84 | CNR1 (0.36) | CNR1CNR2PIK3CDDGAT1 | |
| SCHEMBL31269290 | 0.84 | PIK3CD (0.37) | CNR1CNR2PIK3CDDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |